Trade Abbvie - ABBV CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.29 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.002124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 171.57 |
| Open | 172.05 |
| 1-Year Change | 11.53% |
| Day's Range | 172.05 - 175.95 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 17, 2024 | 175.25 | 4.96 | 2.91% | 170.29 | 176.40 | 170.13 |
| Dec 16, 2024 | 171.57 | 0.81 | 0.47% | 170.76 | 173.20 | 170.45 |
| Dec 13, 2024 | 173.28 | 0.58 | 0.34% | 172.70 | 174.82 | 171.95 |
| Dec 12, 2024 | 173.02 | -1.33 | -0.76% | 174.35 | 175.66 | 171.88 |
| Dec 11, 2024 | 173.79 | -1.42 | -0.81% | 175.21 | 175.68 | 173.74 |
| Dec 10, 2024 | 175.20 | 0.25 | 0.14% | 174.95 | 176.77 | 173.75 |
| Dec 9, 2024 | 176.46 | 1.51 | 0.86% | 174.95 | 177.97 | 174.30 |
| Dec 6, 2024 | 175.69 | -0.07 | -0.04% | 175.76 | 176.62 | 174.10 |
| Dec 5, 2024 | 176.09 | 1.64 | 0.94% | 174.45 | 176.64 | 173.45 |
| Dec 4, 2024 | 176.42 | -3.53 | -1.96% | 179.95 | 179.99 | 175.84 |
| Dec 3, 2024 | 181.35 | -0.54 | -0.30% | 181.89 | 183.40 | 181.15 |
| Dec 2, 2024 | 181.61 | -0.59 | -0.32% | 182.20 | 182.39 | 178.69 |
| Nov 29, 2024 | 182.88 | -0.31 | -0.17% | 183.19 | 183.43 | 182.37 |
| Nov 27, 2024 | 183.01 | 2.17 | 1.20% | 180.84 | 184.15 | 180.79 |
| Nov 26, 2024 | 181.02 | 4.13 | 2.33% | 176.89 | 181.55 | 176.89 |
| Nov 25, 2024 | 176.98 | 0.54 | 0.31% | 176.44 | 180.07 | 176.21 |
| Nov 22, 2024 | 176.83 | 2.80 | 1.61% | 174.03 | 178.78 | 173.45 |
| Nov 21, 2024 | 171.57 | 3.88 | 2.31% | 167.69 | 172.40 | 166.71 |
| Nov 20, 2024 | 167.60 | 0.99 | 0.59% | 166.61 | 167.85 | 165.50 |
| Nov 19, 2024 | 166.45 | 1.50 | 0.91% | 164.95 | 166.92 | 163.78 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
AbbVie Company profile
AbbVie Inc. is a research-based pharmaceutical company, specialising in the discovery and development of biopharmaceuticals and small molecule drugs. With a team of around 29,000 scientists, researchers, manufacturing specialists and communications professionals across the globe, the company introduces new approaches to treating chronic conditions and life-threatening health issues. In 2019, AbbVie was ranked 96th on the Fortune 500 list of America’s biggest companies. More than 30 million patients in over 170 countries are treated by AbbVie’s medicines annually.
Headquartered in North Chicago, Illinois, AbbVie has 22 primary research and manufacturing facilities around the world. The company’s research centres are in the US, Germany and Japan; and its manufacturing sites are located in the USA, Puerto Rico, Ireland, Germany, Italy and Singapore.
The company produces medicines aimed at treating autoimmune diseases, cancers, viruses (including hepatitis C and HIV), neurological and metabolic disorders. According to the Wall Street Journal, in 2016, a specialty drug ibrutinib, retailed by the company, cost from $116,600 to $155,400 a year wholesale in the US. AbbVie estimates global sales of the drug at $5 billion in 2020.
The history of AbbVie started in 2013 when Abbott Laboratories split into two publicly traded companies. One, using the old company name, was to specialise in medical equipment and devices and nutritional products; the other, AbbVie, was to be a research-driven pharmaceutical manufacturer. From the start, AbbVie was interested in acquisitions: in 2014, it acquired ImmuVen for an undisclosed amount, and in 2015, AbbVie acquired oncology firm Pharmacyclics and its treatment for blood cancers.
Presently, the AbbVie share price is listed on the New York Stock Exchange (NYSE). It is also a constituent of both the S&P 100 and 500 indices. In 2018, AbbVie reported its annual revenues of over $32.75 billion. During the same year, the ABBV stock price hit an all-time high of $123. As of July 2019, the company’s market capitalisation was set at around $106.13 billion.
Get the latest news on the Abbvie share price and stay on top of the ABBV share price chart with Capital.com.
| Industry: | Pharmaceuticals (NEC) |
1 N Waukegan Rd
NORTH CHICAGO
ILLINOIS 60064
US
News
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
22:39, 12 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
12:47, 5 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com